

## **Supplemental Information**

Page 1- Supplemental Information: Deal Related Amortization

Page 2 - Supplemental Information: YTD Constant Currency Growth Rates

**Supplemental Information - Deal Related Amortization**

*(\$ Millions, except per Share Data)*

**Deal Amortization**

	Q115	Q215	Q315	Q415	FY15	Q116	Q216	Q316	Q416	FY16
Adjusted Net Income	\$ 14	\$ 19	\$ 22	\$ 19	\$ 75	\$ 13	\$ 17	\$ 19	\$ 14	\$ 63
Deal Amortization	\$ 8	\$ 8	\$ 7	\$ 7	\$ 30	\$ 7	\$ 7	\$ 7	\$ 7	\$ 29
Tax Effect of Deal Amortization	\$ (2)	\$ (2)	\$ (2)	\$ (2)	\$ (9)	\$ (2)	\$ (2)	\$ (2)	\$ (2)	\$ (8)
Adjusted Net Income - Before Deal Amortization	\$ 20	\$ 24	\$ 28	\$ 24	\$ 96	\$ 18	\$ 23	\$ 25	\$ 19	\$ 84
Adjusted Earnings Per Share	\$ 0.28	\$ 0.37	\$ 0.43	\$ 0.37	\$ 1.45	\$ 0.24	\$ 0.34	\$ 0.38	\$ 0.27	\$ 1.23
Deal Amortization, EPS	\$ 0.10	\$ 0.10	\$ 0.10	\$ 0.10	\$ 0.40	\$ 0.10	\$ 0.10	\$ 0.10	\$ 0.09	\$ 0.40
Adjusted Earnings Per Share - Before Deal Amortization	\$ 0.38	\$ 0.47	\$ 0.53	\$ 0.47	\$ 1.85	\$ 0.35	\$ 0.44	\$ 0.48	\$ 0.36	\$ 1.63

*Numbers may not add due to rounding*

**FY16 Product Line Growth Rates in Reported and Constant Currency**

	<b>Q1 % Growth - Constant Currency</b>	<b>Q1 % Growth - Reported Currency</b>	<b>Q2 % Growth - Constant Currency</b>	<b>Q2 % Growth - Reported Currency</b>	<b>Q3 % Growth - Constant Currency</b>	<b>Q3 % Growth - Reported Currency</b>	<b>Q4 % Growth - Constant Currency</b>	<b>Q4 % Growth - Reported Currency</b>	<b>FY16 % Growth - Constant Currency</b>	<b>FY16 % Growth - Reported Currency</b>
Plasma	5%	2%	7%	4%	14%	11%	23%	20%	12%	9%
Blood Center										
Platelet	-14%	-19%	-7%	-13%	4%	0%	13%	9%	-1%	-6%
Red Cell	5%	4%	-8%	-9%	-14%	-15%	-10%	-11%	-7%	-8%
Whole Blood	-13%	-15%	-7%	-10%	-10%	-12%	-2%	-4%	-8%	-10%
	<b>-11%</b>	<b>-14%</b>	<b>-7%</b>	<b>-11%</b>	<b>-4%</b>	<b>-7%</b>	<b>3%</b>	<b>0%</b>	<b>-5%</b>	<b>-8%</b>
Hospital										
Surgical	0%	-5%	0%	-6%	2%	-3%	2%	-4%	1%	-4%
Orthopat	-23%	-26%	-21%	-25%	-35%	-37%	-37%	-40%	-29%	-32%
Diagnostics	21%	23%	25%	24%	18%	17%	22%	20%	21%	21%
	<b>3%</b>	<b>0%</b>	<b>5%</b>	<b>1%</b>	<b>2%</b>	<b>-1%</b>	<b>3%</b>	<b>-1%</b>	<b>3%</b>	<b>0%</b>
<b>Subtotal</b>	<b>-3%</b>	<b>-5%</b>	<b>1%</b>	<b>-3%</b>	<b>4%</b>	<b>2%</b>	<b>11%</b>	<b>8%</b>	<b>4%</b>	<b>0%</b>
Software & Solutions	-1%	-5%	0%	-2%	2%	0%	10%	9%	3%	0%
Equipment & Other	8%	3%	-7%	-12%	-7%	-10%	2%	2%	-2%	-5%
<b>Total Revenue</b>	<b>-2%</b>	<b>-5%</b>	<b>0%</b>	<b>-3%</b>	<b>4%</b>	<b>1%</b>	<b>10%</b>	<b>7%</b>	<b>3%</b>	<b>0%</b>